Bioceres Crop Solutions Statistics

Total Valuation

BCBA:BIOX has a market cap or net worth of ARS 336.92 billion. The enterprise value is 677.80 billion.

Market Cap	336.92B
Enterprise Value	677.80B

Important Dates

The next estimated earnings date is Monday, May 12, 2025.

Earnings Date	May 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.47%
Shares Change (QoQ)	+0.51%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	32.63M

Valuation Ratios

The trailing PE ratio is 217.74.

PE Ratio	217.74
Forward PE	n/a
PS Ratio	0.80
PB Ratio	0.94
P/TBV Ratio	15.49
P/FCF Ratio	n/a
P/OCF Ratio	57.67
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.51, with an EV/FCF ratio of -330.85.

EV / Earnings	438.04
EV / Sales	1.42
EV / EBITDA	10.51
EV / EBIT	17.56
EV / FCF	-330.85

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.82.

Current Ratio	1.32
Quick Ratio	0.93
Debt / Equity	0.82
Debt / EBITDA	5.21
Debt / FCF	-143.75
Interest Coverage	1.24

Financial Efficiency

Return on equity (ROE) is 0.62% and return on invested capital (ROIC) is 3.40%.

Return on Equity (ROE)	0.62%
Return on Assets (ROA)	2.47%
Return on Invested Capital (ROIC)	3.40%
Return on Capital Employed (ROCE)	5.99%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.49
Inventory Turnover	2.06

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -61.65% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-61.65%
50-Day Moving Average	5,590.40
200-Day Moving Average	8,818.45
Relative Strength Index (RSI)	42.63
Average Volume (20 Days)	30,125

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.75

Income Statement

In the last 12 months, BCBA:BIOX had revenue of ARS 420.37 billion and earned 1.55 billion in profits. Earnings per share was 24.35.

Revenue	420.37B
Gross Profit	174.67B
Operating Income	33.72B
Pretax Income	-4.48B
Net Income	1.55B
EBITDA	52.47B
EBIT	33.72B
Earnings Per Share (EPS)	24.35

Full Income Statement

Balance Sheet

The company has 32.16 billion in cash and 294.50 billion in debt, giving a net cash position of -262.34 billion.

Cash & Cash Equivalents	32.16B
Total Debt	294.50B
Net Cash	-262.34B
Net Cash Per Share	n/a
Equity (Book Value)	357.07B
Book Value Per Share	5,089.21
Working Capital	96.70B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.84 billion and capital expenditures -7.89 billion, giving a free cash flow of -2.05 billion.

Operating Cash Flow	5.84B
Capital Expenditures	-7.89B
Free Cash Flow	-2.05B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 41.55%, with operating and profit margins of 8.02% and 0.37%.

Gross Margin	41.55%
Operating Margin	8.02%
Pretax Margin	-1.07%
Profit Margin	0.37%
EBITDA Margin	12.48%
EBIT Margin	8.02%
FCF Margin	n/a

Dividends & Yields

BCBA:BIOX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.47%
Shareholder Yield	0.47%
Earnings Yield	0.46%
FCF Yield	-0.61%

Stock Splits

The last stock split was on January 24, 2024. It was a forward split with a ratio of 2.

Last Split Date	Jan 24, 2024
Split Type	Forward
Split Ratio	2

Scores

BCBA:BIOX has an Altman Z-Score of 1.53. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.53
Piotroski F-Score	n/a